

Table 1. Baseline characteristics of the study population.

	Patients with bleeding (n=50)	Patients without bleeding (n=418)	<i>P</i> value
Sex			0.925
Male	31 (62.0)	262 (62.7)	
Female	19 (38.0)	156 (37.3)	
Age (years)			0.760
<65	16 (32.0)	125 (29.9)	
≥65	34 (68.0)	293 (70.1)	
Body weight (kg)			0.925
<60	12 (25.0)	98 (24.4)	
≥60	36 (75.0)	304 (75.6)	
Creatinine clearance (mL/min)			0.086
<30	5 (10.4)	18 (4.5)	
≥30	43 (89.6)	384 (95.5)	
CHA ₂ DS ₂ -VASc			0.147
<2	3 (6.0)	55 (13.2)	
≥2	47 (94.0)	363 (86.8)	
Modified HAS-BLED			0.870
<2	17 (34.0)	147 (35.2)	
≥2	33 (66.0)	271 (64.8)	
Type of DOAC			0.195
Direct thrombin inhibitors	3 (6.0)	51 (12.2)	
Factor Xa inhibitors	47 (94.0)	367 (87.8)	
Dose of DOAC			0.014
Underdose	18 (36.0)	133 (31.8)	
Standard dose ^a	28 (56.0)	278 (66.5)	
Overdose	4 (8.0)	7 (1.7)	
Alcohol	17 (37.0)	135 (35.4)	0.848
Smoking	7 (14.0)	57 (13.6)	0.944
Comorbidities			
Atrial fibrillation	49 (98.0)	398 (98.5)	0.788
Hypertension	34 (68.0)	282 (67.5)	0.939
Diabetes mellitus	14 (28.0)	119 (28.5)	0.945
Heart failure	5 (10.0)	78 (18.7)	0.130
Previous stroke /TIA/thromboembolism	28 (56.0)	179 (42.8)	0.076

Table 1. Baseline characteristics of the study population. (Cont'd)

	Patients with bleeding (n=50)	Patients without bleeding (n=418)	<i>P</i> value
Previous haemorrhage	4 (8.0)	18 (4.3)	0.277
Anaemia	22 (44.0)	107 (25.6)	0.006
Comedications			
Antiplatelet drugs	3 (6.0)	51 (12.2)	0.195
ACEI/ARBs	19 (38.0)	186 (44.5)	0.381
Beta-blockers	38 (76.0)	295 (70.6)	0.424
Calcium channel blockers	13 (26.0)	116 (27.8)	0.793
Diuretics	11 (22.0)	109 (26.1)	0.533
Statins	28 (56.0)	245 (58.6)	0.723

ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; DOACs: direct oral anticoagulants; NA: not available; TIA: transient ischaemic attack. ^a According to the FDA-approved labelling.